Bumps in the Road: Panniculitis in Children and Adolescents Treated with Vemurafenib

Pediatr Dermatol. 2017 May;34(3):337-341. doi: 10.1111/pde.13148.

Abstract

Vemurafenib is increasingly being used to treat nonmelanoma tumors that are positive for the BRAF V600E mutation. We report three children who presented with panniculitis induced by vemurafenib while undergoing treatment for central nervous system tumors and review the literature.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adolescent
  • Antineoplastic Agents / adverse effects*
  • Central Nervous System Neoplasms / drug therapy*
  • Child
  • Humans
  • Indoles / adverse effects*
  • Male
  • Panniculitis / chemically induced*
  • Sulfonamides / adverse effects*
  • Vemurafenib

Substances

  • Antineoplastic Agents
  • Indoles
  • Sulfonamides
  • Vemurafenib